Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors.

ABSTRACT:

Objective

Our aim was to assess the real-world effectiveness of immune checkpoint inhibitors for treatment of patients with progressive multifocal leukoencephalopathy (PML).

Methods

We conducted a multicenter survey compiling retrospective data from 79 PML patients, including 38 published cases and 41 unpublished cases, who received immune checkpoint inhibitors as add-on to standard of care. One-year follow-up data were analyzed to determine clinical outcomes and safety profile. Logistic regression was used to identify variables associated with 1-year survival.

Results

Predisposing conditions included hematological malignancy (n = 38, 48.1%), primary immunodeficiency (n = 14, 17.7%), human immunodeficiency virus/acquired immunodeficiency syndrome (n = 12, 15.2%), infl

SUBMITTER: Boumaza X 

PROVIDER: S-EPMC10092874 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature